Can Roche Follow Biogen With Success In Alzheimer’s?
Results Expected In November
Analysts still think gantenerumab’s Phase III chances are slim, and it will have to come close to the efficacy reached by Eisai/Biogen’s lecanemab to stay in the Alzheimer’s game. The data are due out next month.
You may also be interested in...
Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.
Having established Enhertu as their first antibody-drug conjugate blockbuster, AstraZeneca and Daiichi Sankyo are looking to challenge Gilead in the TROP2-targeting field as well.
Early data in Gaucher disease suggest Avrobio’s hematopoietic stem cell gene therapy could help patients who do not response to enzyme replacement therapy.